Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
boston top stories
life sciences
national blog main
new york blog main
new york top stories
san francisco blog main
san francisco top stories
7
×
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
indiana blog main
indiana top stories
national
national top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
biotech
novartis
cancer
crispr
eli lilly
fda
biogen
clinical trials
deals
gene therapy
gilead sciences
glaxosmithkline
ipo
medical devices
What
bio
7
×
new
7
×
roundup
cancer
companies
crispr
drug
ipo
isn’t
medicines
pharmaceutical
remains
activity
advantages
allogene
approval
approvals
bails
bar
bets
biogen
biogen’s
biopharma
biopharmaceutical
brand
bridgebio
brings
capital
car
clamped
comes
congress
congressional
convo
covid
cut
date
deal
delays
develop
Language
unset
Current search:
bio
×
new
×
" san francisco top stories "
×
@xconomy.com
4 years ago
Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More
@xconomy.com
4 years ago
Bio Roundup: Ichnos Emerges, Beyond CAR-T, BridgeBio Bails & More
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Bio Roundup: New CRISPR Feud, A NY Splash, Pharma vs. Congress & More
@xconomy.com
5 years ago
Bio Roundup: BIO Diversity, Allogene IPO, CRISPR In Utero & More
@xconomy.com
5 years ago
With $45M Translate Bio Deal, Sanofi Bets Again on mRNA Vaccines